Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar?

Company Overview - Harrow (HROW) shares increased by 11.4% to close at $34.93, supported by high trading volume, contrasting with a 0.7% gain over the past four weeks [1] - The rise in share price is linked to positive investor sentiment regarding the sales growth of its ophthalmic pharmaceutical products in North America, which is anticipated to enhance shareholder value [1] Earnings Expectations - Harrow is projected to report quarterly earnings of $0.01 per share, reflecting a year-over-year increase of 107.7% [2] - Expected revenues for the upcoming quarter are $65.83 million, representing a 34.5% increase from the same quarter last year [2] Stock Performance and Trends - The consensus EPS estimate for Harrow has remained stable over the last 30 days, indicating that stock price movements may not sustain without earnings estimate revisions [3] - Harrow holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] Industry Comparison - Harrow operates within the Zacks Medical - Drugs industry, where another company, electroCore, Inc. (ECOR), experienced an 8.9% decline in its stock price, closing at $6.88 [3] - electroCore's consensus EPS estimate has also remained unchanged at -$0.32, showing a year-over-year change of 15.8% [4]